Biotech / Medical
MGNX -- MacroGenics
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
76 29 0 MGNX
Emcee:  scaram(o)uche Type:  Moderated
CD123-related abstract (preclinical) coming up at ASH, so maybe it's time for a thread. DART is a very old concept.... I was one of the first to try it, but the original concept came from Dartmouth and served as the foundation science for Medarex.

MGD006, Servier has right to license for some geographies.....

One more ASH abstract, not from MGNX.......

Pointer to the pipeline chart, website.....

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
76OT TRIL call: thx, but not yet to a level where put sales are interesting. Watctuck-November 9
75nice call! (not enjoying it at all! ;-)scaram(o)uche-November 9
74Thanks!scaram(o)uche-November 8
73<I am interested in knowing if 012 contributed the variable region to MGD013.Miljenko Zuanic1November 8
72We were all surprised by the size of the 012 deal. I'm not going to try to scaram(o)uche-November 7
71>> I could easily see it coming back some. << I could easily see a scaram(o)uche-November 7
70>> saying folks who sold a few weeks ago are now chasing TRIL stock into bscaram(o)uche-November 7
69Partially OT >>Have you considered that seller's remorse could be extuck-November 7
68>> SITC in general seems be getting regarded as something of a bust, wrt tscaram(o)uche-November 7
67MGA012 at SITC (so far, just the dose escalation phase data): >>A phase tuck-November 7
66Two months in, I'm just pleased that the first patients dosed (a presumptionscaram(o)uche-October 25
65So, Incyte does not believe in PD-1 x LAG-3 bispecific? Why not sub-license,....Miljenko Zuanic-October 25
64Incyte puts big cash upfront for anti-PD1 MGA012, with MGNX retaining combo righscaram(o)uche-October 25
63Not very much, but every bit of info is step forward. Normally, point is can thiMiljenko Zuanic-September 19
62PD1/LAG3: >>Tumor LAG-3 expression is associated with response to combinatuck-September 19
61< MGD013 has a prolonged serum half-life and is being developed for the potenMiljenko Zuanic-September 5
60 MGD013: Zuanic-September 5
59Thanks for your thoughts. Have a great long weekend! Cheers, Tucktuck-September 2
58Well, target (CD3xCD123) may be OK, but 4 days cont. infusion/3 days off dosing Miljenko Zuanic-September 1
57MGD006 may just follow CD3xCD19 path. :-( But I don't see anyone with much otuck-September 1
56Hi Tuck, I guess there us room for some CD3xYYY bispecific, but am not sure thaMiljenko Zuanic-September 1
55MGNX was not putting up any of the development costs after IND, so all they losetuck1September 1
54Another one bite the dust, CD3xCD19, Bispecific (including CDMiljenko Zuanic-August 31
53Another PD-1 deal (from china), IF they (MGNX) want to be "competitive on tMiljenko Zuanic-August 18
52Bullish crossover in MACD and Stochastic oscillators. breakout watch over 18.58.hollyhunter-August 5
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.